Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

LIVER-TRANSPLANTATION FOR ARTERIOHEPATIC DYSPLASIA (ALAGILLES SYNDROME) TRANSPLANT INTERNATIONAL Marino, I. R., Chapchap, P., Esquivel, C. O., ZETTI, G., Carone, E., Borland, L., Tzakis, A. G., Todo, S., Rowe, M. I., Starzl, T. E. 1992; 5 (2): 61-64

Abstract

Thirteen out of 268 children (less than 18 years old) underwent hepatic transplantation (OLT) for end-stage liver disease (ESLD) associated with arteriohepatic dysplasia (AHD). Seven children are alive and well with normal liver function. Six children died, four within 11 days of the operation and the other two at 4 and 10 months after the OLT. Vascular complications with associated septicemia were responsible for the deaths of three children. Two died of heart failure and circulatory collapse, secondary to pulmonary hypertension and congenital heart disease. The remaining patient died of overwhelming sepsis not associated with technical complications. Seven patients had a portoenterostomy or portocholecystostomy early in life; five of these died after the OLT. Severe cardiovascular abnormalities in some of our patients suggest that complete hemodynamic monitoring with invasive studies should be performed in all patients with AHD, especially in cases of documented hypertrophy of the right ventricle. The improved quality of life in our surviving patients confirms the validity of OLT as a treatment of choice in cases of ESLD due to AHD.

View details for Web of Science ID A1992HV82300001

View details for PubMedID 1627241

View details for PubMedCentralID PMC2967196